Linc

Cinclus Pharma is a clinical stage biotechnology company based in Basel, Switzerland, focused on developing small molecules for the treatment of gastric acid-related diseases, particularly erosive gastroesophageal reflux disease (GERD). Founded in 2014, the company is advancing its lead asset, X842, which is designed to address the needs of patients with severe erosive GERD, a condition for which current treatment options are inadequate. In addition to X842, Cinclus is also exploring a dual therapy approach that includes an antibiotic targeting Helicobacter pylori, a bacterium associated with gastric and duodenal issues. Through its innovative research, Cinclus Pharma aims to improve therapeutic outcomes for patients suffering from these challenging conditions.

FluoGuide A/S is a Copenhagen-based company that focuses on developing surgical solutions to enhance cancer treatment outcomes. Founded in 2018, the company is known for its product FG001, which utilizes a fluorophore that specifically binds to cancer cells expressing the urokinase receptor. By employing intelligent targeting techniques, FluoGuide aims to improve surgical precision, thereby reducing patient suffering and increasing the chances of successful treatment. Additionally, the company seeks to lower healthcare costs associated with cancer surgeries.

Oncorena AB develops drugs for cancer. It offers Oncorena that provides pharmacological treatment for metastasing clear cell renal cancer. The company is based in Göteborg, Sweden.

Gesynta Pharma AB is a pharmaceutical company based in Solna, Sweden, focused on developing selective inhibitors of microsomal prostaglandin E synthase-1 (mPGES-1) to address chronic inflammatory conditions and related diseases. The company conducts research on the role of arachidonic acid and aims to create oral treatments for cardiovascular diseases and cancer. Its lead product, GS-248, is a highly potent mPGES-1 inhibitor that has entered clinical phase development. By targeting the pro-inflammatory enzyme mPGES-1, Gesynta Pharma seeks to provide safe and effective anti-inflammatory and pain-relieving pharmaceuticals to improve patient outcomes in various serious diseases. Founded in 2017, the company is committed to advancing innovative therapies in the field of inflammation.